Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Compass Pathfinder Limited

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
From Compass Pathfinder Limited
Via Business Wire
Tickers CMPS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.